Ulcerative Colitis, Active Moderate Clinical Trial
Official title:
Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant
(FMT) for treating patients with mild to moderate Ulcerative Colitis (UC). Even with the
expanding choices of medication for UC, physicians and patients are still in search of highly
effective and safe medications with minimal side effects. FMT has been approved for the
treatment of a bacterial infection called Clostridium difficile. In this setting, FMT has
been proven to be an effective and safe alternative therapy with zero reported serious
adverse events from patients that have had this treatment.
The providers that are conducting this study hypothesize that delivering microbes from a
healthy human gut can help treat the damages caused by UC. This is done by "transplanting"
fecal material, which contains a highly complex and dense community of healthy microbes,
including bacteria, fungi and viruses. This collection of microbes is referred to as a
microbiome. Preliminary studies suggest that alteration of the microbiome can help treat UC.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02818686 -
TD-1473 for Active Ulcerative Colitis (UC)
|
Phase 1 | |
| Completed |
NCT01481142 -
Adacolumn in Refractory UC Patients Trial
|
Phase 4 | |
| Recruiting |
NCT01671956 -
Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
|
Phase 2 |